Holen Sie sich die Stockscreener-App
0.5608
1.32%
-0.0068
Schlusskurs vom Vortag:
$0.5676
Offen:
$0.56
24-Stunden-Volumen:
186.73K
Relative Volume:
0.26
Marktkapitalisierung:
$54.69M
Einnahmen:
$2.24M
Nettoeinkommen (Verlust:
$-136.67M
KGV:
-0.2449
EPS:
-2.29
Netto-Cashflow:
$-102.08M
1W Leistung:
-3.75%
1M Leistung:
-0.27%
6M Leistung:
-46.14%
1J Leistung:
-77.86%
1-Tages-Spanne:
$0.5528
$0.5654
1-Wochen-Bereich:
$0.5505
$0.5999
52-Wochen-Spanne:
$0.3418
$3.29
Century Therapeutics Inc Stock (IPSC) Company Profile
Firmenname
Century Therapeutics Inc
Sektor
Branche
Telefon
215-981-4000
Adresse
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Vergleichen Sie IPSC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.56 | 54.69M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
528.08 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.68 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.99 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-05-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-12 | Eingeleitet | William Blair | Mkt Perform |
| 2021-07-13 | Eingeleitet | BofA Securities | Buy |
| 2021-07-13 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-13 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Century Therapeutics Inc Aktie (IPSC) Neueste Nachrichten
Century Therapeutics Holds Annual Stockholder Meeting By Investing.com - Investing.com South Africa
Century Therapeutics Holds Annual Stockholder Meeting - Investing.com Australia
Century Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
66,797 Shares in Century Therapeutics, Inc. (NASDAQ:IPSC) Acquired by Two Sigma Investments LP - Defense World
Jane Street Group LLC Increases Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Acquired by Squarepoint Ops LLC - Defense World
Two Sigma Advisers LP Takes $52,000 Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Nuveen Asset Management LLC Raises Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - sharewise
Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress - MSN
Deutsche Bank AG Purchases 173,849 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Millennium Management LLC Grows Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Q2 EPS Estimate for Century Therapeutics Raised by Analyst - Defense World
Brokers Issue Forecasts for IPSC Q1 Earnings - Defense World
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress - GlobeNewswire
Chardan Capital Issues Optimistic Forecast for IPSC Earnings - Defense World
Leerink Partnrs Has Negative Forecast for IPSC Q2 Earnings - Defense World
Century Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline - MSN
Chardan Trims Price Target on Century Therapeutics to $6 From $7, Maintains Buy Rating - marketscreener.com
Chardan Capital Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $6.00 - Defense World
Chardan Capital Lowers Price Target for Century Therapeutics (IP - GuruFocus
Chardan Capital Lowers Price Target for Century Therapeutics (IPSC) | IPSC Stock News - GuruFocus
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates - sharewise
Century Therapeutics Expands iPSC Cell Therapy to Europe as Q1 Revenue Surges to $109M - Stock Titan
Marshall Wace LLP Purchases New Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Buys 91,468 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
A closer look at Century Therapeutics Inc (IPSC)’s stock price trends - uspostnews.com
Geode Capital Management LLC Acquires 23,413 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting - MSN
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Century Therapeutics (IPSC) Expected to Announce Earnings on Thursday - Defense World
An Analysis of Century Therapeutics Inc (IPSC)’s Potential Price Growth - knoxdaily.com
Renaissance Technologies LLC Boosts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Market Insight: Century Therapeutics Inc (IPSC)’s Notable Drop, Closing at 0.50 - DWinneX
Century Therapeutics to Present Preclinical Data at ASGCT 28th Annual Meeting on Novel iPSC-Derived Cell Therapies for Autoimmune Diseases and Cancer - Nasdaq
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting - GlobeNewswire
Century Therapeutics Reveals Groundbreaking Cancer-Fighting Cell Therapy Data at Major Scientific Conference - Stock Titan
IPSCCentury Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Is it possible to buy Century Therapeutics Inc(IPSC) shares at a good price now? - uspostnews.com
Century Therapeutics Inc (IPSC): A Sitting Duck With -825.93% Upside Potential - Stocksregister
H.C. Wainwright maintains Buy rating on Century Therapeutics stock - Investing.com
Century Therapeutics Inc (IPSC)’s financial ratios: A comprehensive overview - DWinneX
H.C. Wainwright maintains Buy rating on Century Therapeutics stock By Investing.com - Investing.com UK
Century Therapeutics Inc [IPSC] Stock sold by Insider Pfeiffenberger Brent for $1375.0 - knoxdaily.com
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MSN
Finanzdaten der Century Therapeutics Inc-Aktie (IPSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Century Therapeutics Inc-Aktie (IPSC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Farid Adrienne | Chief Operations Officer |
Jun 09 '25 |
Sale |
0.62 |
552 |
343 |
250,141 |
| Pfeiffenberger Brent | President and CEO |
Jun 09 '25 |
Sale |
0.62 |
475 |
295 |
1,681,783 |
| Russotti Gregory | See Remarks |
Jun 09 '25 |
Sale |
0.62 |
526 |
327 |
392,047 |
1.37%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):